The fittest founder in the room got cancer. Here’s how he used AI to fight back

Published 27 June 2026 · tech

Conno Christou doesn’t leave things to chance. He tracks his sleep with a Whoop band, cross-references it with an Oura ring, and gets nearly 100

Conno Christou doesn’t leave things to chance. He tracks his sleep with a Whoop band, cross-references it with an Oura ring, and gets nearly 100 biomarkers checked every year. He had been doing the annual bloodwork for four consecutive years, following the protocols of longevity researchers like Peter Attia and Rhonda Patrick. He was optimizing his supplements, his circadian rhythm, his protein intake. At 35, building his second company, he was as dialed-in on the latest in health research as anyone he knew. His last checkup, in 2025, was green across the board. “It was the best I’d had in years,” he says. Then, after a workout, his arm swelled. He didn’t think much of it at first. A week passed before he saw a doctor, who found two blood clots in his veins and scheduled surgery. But the pre-op exams changed everything. A doctor walked back into the room and told him the procedure wasn’t happening. “We see an 11-by-11-by-8 centimeter mass behind your sternum,” the doctor said. A biopsy confirmed what Christou had never before even contemplated. He had an aggressive, fast-growing form of non-Hodgkin’s lymphoma — a rare diagnosis affecting roughly one in 420,000 people, caused by a random genetic mutation with no connection to lifestyle, diet, or stress. The tumor had only existed for about three months. In three more weeks, it would have reached stage four. “Lucky in my unluckiness,” Christou told this editor this week from his home in Athens, where he lives part time. “It was only found because I went in for something else entirely.” What followed was an education in the limits of the medical system, and in what a determined patient can do about that with tools now available. His first oncologist, a renowned specialist, recommended the lighter of two available chemotherapy regimens.

Christou booked his first infusion three days out. Then, the night before, he sought a second opinion. That doctor didn’t hesitate. He recommended the harder regimen — continuous in-hospital infusion, cycling every three weeks across six months — citing Christou’s specific pathology. The lighter treatment carried roughly a 60% success rate for his presentation. The aggressive one brought that number to around 85%. Two world-class doctors. Diametrically opposite recommendations. “As founders, we hold the wheel,” Christou says of the propensity of many people to accept what they are told — and why more should not. “You hear many things. You don’t have to follow the first advice.” He didn’t opt to just follow the second advice, either. Over the next two days, he gathered 12 opinions in total — drawing on his professional network, reaching out to hematologists and oncologists in the US and abroad, calling in every favor he could. Eleven to one voted in favor of the harder path. He took it. The decision, he says, didn’t feel brave so much as logical. When the stakes are existential, you collect data. Over six months of treatment, Christou approached chemotherapy the way he approached building a company: as a marathon of sprints, each of them with a finite cycle, each week filled with data points. He had done a mandatory 25-month military service in Cyprus at age 18 and he borrowed from that experience, too. He was going to be a good soldier, he told himself. Trust the process. Six cycles. Get through it. He wore his Whoop throughout, and found it remarkably accurate at predicting the days his immune system would bottom out, sometimes flagging them before symptoms arrived. He kept a symptom journal using voice transcription, logging every shift, every side effect, every medication and counter-medication. He narrowed his focus to three variables: sleep, nutrition, and, first and foremost, psychology.